Ketamine subcutaneous - Bexson Biomedical
Alternative Names: BB-106Latest Information Update: 24 May 2023
At a glance
- Originator Bexson Biomedical
- Class Analgesics; Antidepressants; Behavioural disorder therapies; Cyclohexanes; General anaesthetics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute pain; Mental disorders